Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study

摘要

Treatment of erythrodermic psoriasis (EP) is challenging because patients with current or history of EP are excluded in pivotal trials.[1] Ixekizumab and secukinumab are both interleukin (IL)-17A blockers. Ixekizumab has demonstrated effectiveness in patients with plaque type psoriasis and poor response to prior secukinumab and is especially effective in patients with secondary failure.[2],[3] The effectiveness of ixekizumab in EP up to week 12 has also been reported.[4] However, drug survival of biologics in EP is lower than in plaque psoriasis, and efficacy of ixekizumab peaks around 12–16 weeks. Thus, it is important to understand the long-term effectiveness of ixekizumab in EP.